Research Article

Stress Degradation Behavior of Paliperidone, an Antipsychotic Drug, and Development of Suitable Stability-Indicating RP-LC Method

Table 4

Validation data results of related substances and assay of paliperidone.

CompoundRelated substances resultsAssay results
IMP-AIMP-BIMP-CIMP-DIMP-Epaliperidone

Precision (mean results ± %RSD)
 Method precision ( 𝑛 = 6 ) 0 . 1 6 4 ± 1 . 2 4 0 . 1 6 3 ± 0 . 6 1 0 . 5 4 6 ± 3 . 8 5 0 . 1 4 9 ± 0 . 6 7 0 . 0 5 9 ± 1 . 6 9 9 9 . 0 ± 0 . 2 1
 Intermediate Precision ( 𝑛 = 6 ) 0 . 1 5 8 ± 0 . 6 3 0 . 1 5 9 ± 0 . 0 0 0 . 5 2 6 ± 0 . 5 7 0 . 1 5 1 ± 0 . 6 6 0 . 0 6 2 ± 0 . 0 0 1 0 0 . 3 ± 0 . 3 5
 Overall results ( 𝑛 = 1 2 ) 0 . 1 6 0 ± 1 . 2 5 0 . 1 6 1 ± 1 . 2 4 0 . 5 3 6 ± 3 . 3 9 0 . 1 5 0 ± 1 . 3 3 0 . 0 6 1 ± 3 . 2 8 9 9 . 7 ± 0 . 7 5

 Limit of detection (LOD)
 LOD (μg mL−1)0.0300.0390.1550.0710.0460.065
 LOD (% w.r.t. test)0.0030.0040.0160.0070.0050.007

 Limit of quntitations (LOQ)
 LOQ (μg mL−1)0.0900.1190.4700.2140.1410.197
 LOQ (% w.r.t. test)0.0090.0120.0470.0210.0140.020

Linearity: for related substances LOQ to 250% of specification level and for assay 50 to 150% of TAC
 Correlation coefficient (r)0.999660.999780.999730.999360.999250.99996
 Slope22910.4935819.2319598.9430803.2936086.7831580.49
 Intercept −100.38 −653.37 1214.32 −172.37 −631.62 −1131.83

Accuracy (mean recovery ± %RSD): LOQ to 150 % of specification level
 LOQ 9 2 . 5 9 ± 6 . 9 3 8 6 . 1 1 ± 5 . 5 9 1 0 6 . 5 1 ± 7 . 3 6 9 0 . 4 8 ± 5 . 2 7 9 2 . 3 1 ± 8 . 3 3
 50% 9 3 . 8 6 ± 2 . 1 4 9 5 . 2 2 ± 0 . 7 5 1 1 4 . 9 3 ± 1 . 0 4 1 0 0 . 0 0 ± 1 . 3 5 9 1 . 1 1 ± 1 . 6 9
 100% 1 0 4 . 1 7 ± 1 . 9 3 9 7 . 6 0 ± 0 . 7 7 1 0 7 . 5 4 ± 0 . 6 8 9 9 . 5 5 ± 1 . 4 2 9 4 . 6 7 ± 0 . 7 0
 150% 1 0 3 . 3 6 ± 0 . 6 5 9 7 . 6 8 ± 0 . 5 1 1 0 4 . 3 7 ± 0 . 4 4 9 9 . 8 5 ± 1 . 4 4 9 4 . 8 1 ± 0 . 5 4

% w.r.t. test LOD LOQ values are in % with respect to test concentration of 1000 μg mL−1.
TAC, Target analytical concentration that is, 100 μg mL−1.